⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 19, 2024Clinical RadiologyOpen Access

MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis

He Qi Yi Hou Zhe Zheng Min Zheng Xiaorong Sun Ligang Xing

View Full Paper

Ask AI

Bookmark

Share

Abstract

To develop and validate models based on magnetic resonance imaging (MRI) radiomics for predicting the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients with brain metastases.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Qi et al. (2024) studied this question.

synapsesocial.com/papers/68e73502b6db6435876aea19 https://doi.org/10.1016/j.crad.2024.02.016

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Radiomics using contrast-enhanced T1-weighted imaging and clinical features for predicting response to EGFR-TKIs in EGFR-mutated non-small cell lung cancer patients with brain metastasesOriginal Research · 2026
2Peritumoral and intratumoral magnetic resonance imaging-based radiomics of brain metastases for predicting the response to EGFR-tyrosine kinase inhibitors in metastatic non-small cell lung cancer2025
3Prediction of EGFR Mutation Status in Non-small Cell Lung Cancer Based on Multiparametric MRI Radiomics2025
4Computed tomography‐based radiomics and clinical‐genetic features for brain metastasis prediction in patients with stage <scp>III</scp>/<scp>IV</scp> epidermal growth factor receptor‐mutant non‐small‐cell lung cancer2024 · 4 citations
5Multiparametric MRI-based radiomics for predicting the EGFR mutation status in patients with non-small cell lung cancer2025